Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for RenovoRx, Inc. as of June 30, 2025 is 0.66 MM.
- The operating income for RenovoRx, Inc. as of June 30, 2025 is -11.25 MM.
- The net income for RenovoRx, Inc. as of June 30, 2025 is -10.66 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 0.66 | -11.25 | -10.66 |
2025-03-31 | 0.24 | -11.60 | -10.16 |
2024-12-31 | 0.04 | -10.97 | -8.81 |
2024-09-30 | -10.12 | -9.16 | |
2024-06-30 | -10.27 | -8.11 | |
2024-03-31 | -10.61 | -8.05 | |
2023-12-31 | -11.40 | -10.23 | |
2023-09-30 | -11.79 | -9.16 | |
2023-06-30 | -10.97 | -9.88 | |
2023-03-31 | -10.21 | -10.14 | |
2022-12-31 | -9.95 | -9.89 | |
2022-09-30 | -10.14 | -10.09 | |
2022-06-30 | -9.37 | -9.46 | |
2022-03-31 | -7.62 | -8.18 | |
2021-12-31 | -5.67 | -6.32 | |
2021-09-30 | -3.95 | -4.85 | |
2021-06-30 | -3.47 | -4.43 | |
2021-03-31 | -3.20 | -3.90 | |
2020-12-31 | -3.20 | -3.80 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | -0.39 | -0.39 |
2024-12-31 | -0.40 | |
2024-09-30 | -0.49 | -0.49 |
2024-06-30 | -0.54 | -0.54 |
2024-03-31 | -0.68 | -0.68 |
2023-12-31 | -0.99 | |
2023-09-30 | -0.93 | -0.93 |
2023-06-30 | -1.04 | -1.04 |
2023-03-31 | -1.12 | -1.12 |
2022-12-31 | -1.09 | |
2022-09-30 | -1.09 | -1.09 |
2022-06-30 | -1.10 | -1.10 |
2022-03-31 | -1.18 | -1.18 |
2021-12-31 | -1.21 | |
2021-09-30 | -1.48 | -1.48 |
2021-06-30 | -1.98 | -1.98 |
2021-03-31 | -1.75 | -1.75 |
2020-12-31 | -1.72 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for RenovoRx, Inc. as of June 30, 2025 is -10.31 MM.
- The cash from investing activities for RenovoRx, Inc. as of June 30, 2025 is -0.01 MM.
- The cash from financing activities for RenovoRx, Inc. as of June 30, 2025 is 10.89 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -10.31 | -0.01 | 10.89 |
2025-03-31 | -10.30 | -0.01 | 20.51 |
2024-12-31 | -9.12 | -0.01 | 15.12 |
2024-09-30 | -8.75 | 0.00 | 15.09 |
2024-06-30 | -9.28 | 0.00 | 15.07 |
2024-03-31 | -9.76 | 0.00 | 10.42 |
2023-12-31 | -10.26 | 2.03 | 5.01 |
2023-09-30 | -9.89 | 5.01 | 5.01 |
2023-06-30 | -9.83 | 8.00 | 5.01 |
2023-03-31 | -9.42 | 0.00 | 0.02 |
2022-12-31 | -8.81 | -2.03 | 0.04 |
2022-09-30 | -9.69 | -5.01 | 0.06 |
2022-06-30 | -8.13 | -8.00 | 17.35 |
2022-03-31 | -7.02 | -0.01 | 19.32 |
2021-12-31 | -5.92 | -0.01 | 19.33 |
2021-09-30 | -4.33 | -0.01 | 19.76 |
2021-06-30 | -3.90 | -0.01 | 2.47 |
2021-03-31 | -3.48 | 1.92 | |
2020-12-31 | -3.53 | 3.20 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/book for RenovoRx, Inc. as of June 30, 2025 is 3.65.
- The p/tbv for RenovoRx, Inc. as of June 30, 2025 is 3.65.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 3.65 | 3.65 | |
2025-03-31 | -3.88 | 5.03 | 5.03 |
2024-12-31 | 4.72 | 4.72 | |
2024-09-30 | -3.13 | 2.74 | 2.74 |
2024-06-30 | -3.45 | 15.72 | 15.72 |
2024-03-31 | -2.53 | 3,870.21 | 3,870.21 |
2023-12-31 | -2.68 | 4,099.03 | 4,099.03 |
2023-09-30 | -1.44 | 11.97 | 11.97 |
2023-06-30 | -2.24 | 6.97 | 6.97 |
2023-03-31 | -3.19 | 3.87 | 3.87 |
2022-12-31 | 2.62 | 2.62 | |
2022-09-30 | 1.83 | 1.83 | |
2022-06-30 | -2.28 | 1.49 | 1.49 |
2022-03-31 | -4.13 | 1.70 | 1.70 |
2021-12-31 | -8.88 | 2.45 | 2.45 |
2021-09-30 | -11.37 | -10.93 | -10.93 |
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for RenovoRx, Inc. as of June 30, 2025 is -0.30.
- The ebit (3y)/ev for RenovoRx, Inc. as of June 30, 2025 is -0.28.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.30 | -0.28 |
2025-03-31 | -0.35 | -0.35 |
2024-12-31 | -0.39 | -0.41 |
2024-09-30 | -0.59 | -0.67 |
2024-06-30 | -0.34 | -0.38 |
2024-03-31 | -0.46 | -0.42 |
2023-12-31 | -0.43 | -0.38 |
2023-09-30 | -1.19 | -0.96 |
2023-06-30 | -0.53 | -0.42 |
2023-03-31 | -0.31 | -0.23 |
2022-12-31 | -0.55 | -0.27 |
2022-09-30 | -0.60 | -0.30 |
2022-06-30 | -1.47 | -0.99 |
2022-03-31 | -0.58 | -0.43 |
2021-12-31 | -0.11 | -0.10 |
2021-09-30 | -0.07 | -0.02 |
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 |
Management Effectiveness
- The roa for RenovoRx, Inc. as of June 30, 2025 is -0.85.
- The roe for RenovoRx, Inc. as of June 30, 2025 is -1.10.
- The roic for RenovoRx, Inc. as of June 30, 2025 is -0.76.
- The croic for RenovoRx, Inc. as of June 30, 2025 is 0.76.
- The ocroic for RenovoRx, Inc. as of June 30, 2025 is -0.77.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.85 | -1.10 | -0.76 | 0.76 | -0.77 |
2025-03-31 | -1.91 | -5.19 | -1.30 | 0.90 | -1.24 |
2024-12-31 | -6.25 | -1.30 | 0.90 | -1.24 | |
2024-09-30 | -2.31 | -1,352.17 | -0.88 | 0.62 | -1.00 |
2024-06-30 | -1.77 | -2.47 | -4.56 | 0.38 | -5.52 |
2024-03-31 | -1.12 | -1,526.83 | 22.17 | -1,647.67 | |
2023-12-31 | -0.99 | -1.12 | -1,526.83 | 22.17 | -1,647.67 |
2023-09-30 | -0.88 | -0.98 | -8.31 | 2.68 | -8.27 |
2023-06-30 | -0.90 | -1.00 | -8.31 | 2.68 | -8.27 |
2023-03-31 | -0.71 | -0.79 | -3.12 | -2.89 | -2.89 |
2022-12-31 | -0.55 | -0.57 | -1.24 | -1.80 | -1.19 |
2022-09-30 | -0.52 | -0.54 | -1.24 | -1.80 | -1.19 |
2022-06-30 | -3.78 | -0.94 | 0.12 | -0.80 | |
2022-03-31 | -4.95 | -0.65 | 0.98 | -0.56 | |
2021-12-31 | -2.53 | -0.31 | 0.66 | -0.19 | |
2021-09-30 | -3.03 | -0.22 | 0.69 | -20.31 | |
2021-06-30 | -1.95 | -3.03 | -13.35 | -4.36 | -11.75 |
2021-03-31 | -1.72 | -2.66 | |||
2020-12-31 | -1.67 | -2.59 |
Gross Margins
- The gross margin for RenovoRx, Inc. as of June 30, 2025 is 0.61.
- The net margin for RenovoRx, Inc. as of June 30, 2025 is -42.32.
- The operating margin for RenovoRx, Inc. as of June 30, 2025 is -48.35.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.61 | -42.32 | -48.35 |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Identifiers and Descriptors
Central Index Key (CIK) | 1574094 |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |